pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2020-30-1-102-108pulmo-1285Research ArticleОБЗОРЫREVIEWИнтерстициальное поражение легких при системной склеродермии (обзор литературы и собственное клиническое наблюдение)Interstitial lung lesion in systemic scleroderma (literature review and personal observation)НашатыреваМ. С.NashatyrevaM. S.

Нашатырева Мария Сергеевна – аспирант кафедры клинической аллергологии и пульмонологии

664049, Иркутск, мкр Юбилейный, 100тел.: (3952) 22-85-77 

Mariya S. Nashatyreva, Postgraduate student

mkr Yubileynyy 100, Irkutsk, 664079tel.: (3952) 22-85-77 

volga-89@list.ruТрофименкоИ. Н.TrofimenkoI. N.

Трофименко Ирина Николаевна – д. м. н., доцент кафедры клинической аллергологии и пульмонологии

664049, Иркутск, мкр Юбилейный, 100тел.: (9148) 77-80-96 

Irina N. Trofimenko, Doctor of Medicine, Associate Professor, Department of Clinical Allergology and Pulmonology

mkr Yubileynyy 100, Irkutsk, 664079tel.: (9148) 77-80-96 

tin11@mail.ruЧернякБ. А.ChernyakB. A.

Черняк Борис Анатольевич – д. м. н., профессор, заведующий кафедрой клинической аллергологии и пульмонологии

664049, Иркутск, мкр Юбилейный, 100тел.: (9025) 68-78-70 

Boris A. Chernyak, Doctor of Medicine, Professor, Head of Department of Clinical Allergology and Pulmonology

mkr Yubileynyy 100, Irkutsk, 664079tel.: (9025) 68-78-70 

ba.chernyak@gmail.comИркутская государственная медицинская академия последипломного образования – филиал Федерального государственного бюджетного образовательного учреждения дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияIrkutsk State Medical Academy of Postgraduate Education – Branch Campus of Irkutsk State Medical Academy of Postgraduate TrainingRussian Federation202021042020301102108Copyright © Нашатырева М.С., Трофименко И.Н., Черняк Б.А., 20202020Нашатырева М.С., Трофименко И.Н., Черняк Б.А.Nashatyreva M.S., Trofimenko I.N., Chernyak B.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1285

Интерстициальное поражение является одним из самых частых вариантов патологии легких у больных системной склеродермией (ССД). В большинстве случаев интерстициальное заболевание легких (ИЗЛ) формируется в период развернутой клинической картины ССД, однако оно может манифестировать с интерстициального поражения легких, что существенно затрудняет раннюю нозологическую диагностику. Среди вариантов интерстициального поражения легких при ССД чаще всего встречаются паттерны неспецифической и обычной интерстициальной пневмонии. Клинические проявления ИЗЛ при ССД неспецифичны и существенно различаются между пациентами от бессимптомных до быстропрогрессирующей дыхательной недостаточности. Ранняя диагностика субклинического интерстициального поражения легких при ССД осуществляется при проведении компьютерной томографии легких высокого разрешения. При своевременной диагностике прогрессирующих форм ИЗЛ при ССД требуется активная иммуносупрессивная терапия. В представленном клиническом наблюдении продемонстрирован случай поздней диагностики ИЗЛ при ССД.

Interstitial lesion is one of the most common lung pathologies in patients with systemic scleroderma (SS) In most cases, interstitial lung disease (ILD) is formed during the detailed clinical picture of SS, but it can manifest from interstitial lung disease, which significantly complicates early nosological diagnosis. Patterns of non-specific and common interstitial pneumonia are most often found among the variants of interstitial lung lesion at SS Clinical manifestations of ILD-SS are non-specific and vary significantly between patients from asymptomatic to rapidly progressing respiratory failure. Early diagnosis of subclinical interstitial pulmonary lesion at SS is carried out using high-resolution computed tomography. Active immunosuppressive therapy is required for timely diagnosis of progressive forms of ILD-SS The presented clinical study demonstrates a case of late diagnosis of ILD-SS

интерстициальное заболевание легкихсистемная склеродермияinterstitial lung diseasesystemic sclerodermaReferencesАнаньева Л.П. Диагностика и лечение интерстициального поражения легких при системной склеродермии. Современная ревматология. 2018; 12 (2): 12–21. DOI: 10.14412/1996-7012-2018-2-12-21.Anan'eva L.P. [Diagnosis and treatment of interstitial lung disease in scleroderma systematica]. Sovremennaya revmatologiya. 2018; 12 (2): 12–21/ DOI: 10.14412/1996-70122018-2-12-21 (in Russian).Ferri C., Valentini G., Cozzi F. et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81 (2): 139–153. DOI: 10.1097/00005792-200203000-00004.Ferri C., Valentini G., Cozzi F. et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002; 81 (2): 139–153. DOI: 10.1097/00005792-200203000-00004.Chowaniec M., Skoczyńska M., Sokolik R. et al. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia. 2018; 56 (4): 249–254. DOI: 10.5114/reum.2018.77977.Chowaniec M., Skoczyńska M., Sokolik R. et al. Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia. 2018; 56 (4): 249–254. DOI: 10.5114/reum.2018.77977.Cottin V., Brown K.K. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir. Res. 2019; 20: 13. DOI: 10.1186/s12931-019-0980-7.Cottin V., Brown K.K. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir. Res. 2019; 20: 13. DOI: 10.1186/s12931-019-0980-7.Cappelli S., Bellando Randone S., Camiciottoli G. et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur. Respir. Rev. 2015; 24 (137): 411–419. DOI: 10.1183/16000617.00002915.Cappelli S., Bellando Randone S., Camiciottoli G. et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur. Respir. Rev. 2015; 24 (137): 411–419. DOI: 10.1183/16000617.00002915.Varga J. Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma). UpToDate. Available at: https://www.uptodate.com/contents/clinical-manifestations-evaluation-and-diagnosis-ofinterstitial-lung-disease-in-systemic-sclerosis-sclerodermaVarga J. Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma). UpToDate. Available at: https://www.uptodate.com/contents/clinical-manifestations-evaluation-and-diagnosis-ofinterstitial-lung-disease-in-systemic-sclerosis-sclerodermaValeyre D., Duchemann B., Nunes H. et al. Interstitial lung diseases. Respiratory Epidemiology. ERS Monogr., chapter 6. 2014; 65: XIV–XVII.Valeyre D., Duchemann B., Nunes H. et al. Interstitial lung diseases. Respiratory Epidemiology. ERS Monogr., chapter 6. 2014; 65: XIV–XVII.Mathai S.C., Danoff S.K. Management of interstitial lung disease associated with connective tissue disease. Br. Med. J. 2016; 352: h6819. DOI: 10.1136/bmj.h6819.Mathai S.C., Danoff S.K. Management of interstitial lung disease associated with connective tissue disease. Br. Med. J. 2016; 352: h6819. DOI: 10.1136/bmj.h6819.Jung E., Suh C.H., Kim H.A., Jung J.Y. Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch. Rheumatol. 2018; 33 (3): 322–327. DOI: 10.5606/ArchRheumatol.2018.6630.Jung E., Suh C.H., Kim H.A., Jung J.Y. Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch. Rheumatol. 2018; 33 (3): 322–327. DOI: 10.5606/ArchRheumatol.2018.6630.Khanna D., Nagaraja V., Tseng C.H. et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosisassociated interstitial lung disease trials. Arthritis Res. Ther. 2015; 17: 372. DOI: 10.1186/s13075-015-0872-2.Khanna D., Nagaraja V., Tseng C.H. et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosisassociated interstitial lung disease trials. Arthritis Res. Ther. 2015; 17: 372. DOI: 10.1186/s13075-015-0872-2.Antoniou K.M., Margaritopoulos G., Economidou F. et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur. Respir. J. 2009; 33 (4): 882–896. DOI: 10.1183/09031936.00152607.Antoniou K.M., Margaritopoulos G., Economidou F. et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur. Respir. J. 2009; 33 (4): 882–896. DOI: 10.1183/09031936.00152607.Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis. 2007; 66 (7): 940–944. DOI: 10.1136/ard.2006.066068.Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis. 2007; 66 (7): 940–944. DOI: 10.1136/ard.2006.066068.Rubio-Rivas M., Royo C., Simeón C.P. et al. Mortality and survival in systemic sclerosis: systematic review and metaanalysis. Semin. Arthritis Rheum. 2014; 44 (2): 208–219. DOI: 10.1016/j.semarthrit.2014.05.010.Rubio-Rivas M., Royo C., Simeón C.P. et al. Mortality and survival in systemic sclerosis: systematic review and metaanalysis. Semin. Arthritis Rheum. 2014; 44 (2): 208–219. DOI: 10.1016/j.semarthrit.2014.05.010.Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165 (12): 1581–1586. DOI: 10.1164/rccm.2106012.Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165 (12): 1581–1586. DOI: 10.1164/rccm.2106012.Лесняк В.Н., Ананьева Л.П., Конева О.А. и др. Полуколичественные визуальные методы оценки выраженности интерстициальных поражений легких по данным компьютерной томографии при системной склеродермии. Пульмонология. 2017; 27 (1): 41–50. DOI: 10.18093/0869-0189-2017-27-1-41-50.Lesnyak V.N., Anan'eva L.P., Koneva O.A. et al. [Semiquantification image methods for assessing severity of scleroderma-associated interstitial lung disease according to computed tomography data]. Pul'monologiya. 2017; 27 (1): 41–50. DOI: 10.18093/0869-0189-2017-27-1-41-50 (in Russian).Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology. 2016; 21 (2): 245–258. DOI: 10.1111/resp.12588.Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology. 2016; 21 (2): 245–258. DOI: 10.1111/resp.12588.Wells A.U., Hansell D.M., Corrin B. et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992; 47 (9): 738–742. DOI: 10.1136/thx.47.9.738.Wells A.U., Hansell D.M., Corrin B. et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992; 47 (9): 738–742. DOI: 10.1136/thx.47.9.738.Steen V.D., Conte C., Owens G.R., Medsger T.A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37 (9): 1283–1289. DOI: 10.1002/art.1780370903.Steen V.D., Conte C., Owens G.R., Medsger T.A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37 (9): 1283–1289. DOI: 10.1002/art.1780370903.Jaeger V.K., Wirz E.G., Allanore Y. et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016; 11(10): e0163894. DOI: 10.1371/journal.pone.0163894.Jaeger V.K., Wirz E.G., Allanore Y. et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016; 11 (10): e0163894. DOI: 10.1371/journal.pone.0163894.Nihtyanova S.I., Schreiber B.E., Ong V.H. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014; 66 (6): 1625–1635. DOI: 10.1002/art.38390.Nihtyanova S.I., Schreiber B.E., Ong V.H. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014; 66 (6): 1625–1635. DOI: 10.1002/art.38390.Tashkin D.P., Elashoff R., Clements P.J. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 354 (25): 2655–2666. DOI: 10.1056/NEJMoa055120.Tashkin D.P., Elashoff R., Clements P.J. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 354 (25): 2655–2666. DOI: 10.1056/NEJMoa055120.Tashkin D.P., Roth M.D., Clements P.J. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 2016; 4 (9): 708–719. DOI: 10.1016/S2213-2600(16)30152-7.Tashkin D.P., Roth M.D., Clements P.J. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 2016; 4 (9): 708–719. DOI: 10.1016/S2213-2600(16)30152-7.Huang H., Feng R., Li S. et al. A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: a CARE-compliant article. Medicine (Baltimore). 2016; 95 (27): e4113. DOI: 10.1097/MD.0000000000004113.Huang H., Feng R., Li S. et al. A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: a CARE-compliant article. Medicine (Baltimore). 2016; 95 (27): e4113. DOI: 10.1097/MD.0000000000004113.Miura Y., Saito T., Fujita K. et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31 (3): 235–238.Miura Y., Saito T., Fujita K. et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31 (3): 235–238.Duarte A.C., Santos M.J., Cordeiro A. Anti-fibrotic nintedanib – a new opportunity for systemic sclerosis patients? Clin. Rheumatol. 2018; 37 (4): 1123–1127. DOI: 10.1007/s10067-017-3867-3.Duarte A.C., Santos M.J., Cordeiro A. Anti-fibrotic nintedanib – a new opportunity for systemic sclerosis patients? Clin. Rheumatol. 2018; 37 (4): 1123–1127. DOI: 10.1007/s10067-017-3867-3.Distler O., Brown K.K., Distler J.H.W. et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin. Exp. Rheumatol. 2017; 35, Suppl. 106 (4): 75–81.Distler O., Brown K.K., Distler J.H.W. et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin. Exp. Rheumatol. 2017; 35, Suppl. 106 (4): 75–81.Plastiras S.C., Karadimitrakis S.P., Ziakas P.D. et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006; 55 (4): 598–602. DOI: 10.1002/art.22099.Plastiras S.C., Karadimitrakis S.P., Ziakas P.D. et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006; 55 (4): 598–602. DOI: 10.1002/art.22099.Kallenbach J., Prinsloo I., Zwi S. Progressive systemic sclerosis complicated by diffuse pulmonary haemorrhage. Thorax. 1977; 32 (6): 767–770. DOI: 10.1136/thx.32.6.767.Kallenbach J., Prinsloo I., Zwi S. Progressive systemic sclerosis complicated by diffuse pulmonary haemorrhage. Thorax. 1977; 32 (6): 767–770. DOI: 10.1136/thx.32.6.767.Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012; 380 (9842): 689–698. DOI: 10.1016/S0140-6736(12)61079-4.Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012; 380 (9842): 689–698. DOI: 10.1016/S0140-6736(12)61079-4.

The authors declare that there are no conflicts of interest present.